National cancer institute. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy2

Cell Line, Tumor Tumor Cells, Cultured

Organisms3

Mice, Nude Rats, Inbred F344 Vegetables

Diseases46

Neoplasms Breast Neoplasms Lung Neoplasms Prostatic Neoplasms Ovarian Neoplasms Colorectal Neoplasms Colonic Neoplasms Neoplasm Metastasis Neoplasm Recurrence, Local Stomach Neoplasms Neoplasms, Second Primary Adenocarcinoma Carcinoma, Non-Small-Cell Lung Pancreatic Neoplasms Disease Progression Neoplasm Invasiveness Carcinoma Uterine Cervical Neoplasms Urinary Bladder Neoplasms Skin Neoplasms Genetic Predisposition to Disease Kidney Neoplasms Melanoma Carcinoma, Squamous Cell Carcinoma, Small Cell Neutropenia Leukemia, Lymphocytic, Chronic, B-Cell Genital Neoplasms, Female Rectal Neoplasms Head and Neck Neoplasms Brain Neoplasms Liver Neoplasms Vomiting Nausea Neoplasms, Experimental Neoplasms, Ductal, Lobular, and Medullary Lymphoma, Non-Hodgkin Gastrointestinal Neoplasms Miosis Neoplasms, Radiation-Induced Thyroid Neoplasms Precursor Cell Lymphoblastic Leukemia-Lymphoma Bone Neoplasms Sarcoma Fatigue Radiation Injuries

Chemicals and Drugs38

Antineoplastic Agents Cisplatin Tumor Markers, Biological Paclitaxel Fluorouracil Organoplatinum Compounds Deoxycytidine Antimetabolites, Antineoplastic Antineoplastic Agents, Phytogenic Prostate-Specific Antigen Carcinogens Neoplasm Proteins Antineoplastic Agents, Alkylating Tamoxifen Vinblastine Taxoids Cyclophosphamide Receptors, Estrogen Dacarbazine Camptothecin Cancer Vaccines Topotecan Carboplatin DNA, Neoplasm Quinazolines Vidarabine Phosphate Antibodies, Monoclonal, Humanized Antibodies, Monoclonal Chromium Compounds Vincristine Antineoplastic Agents, Hormonal Doxorubicin Tumor Suppressor Protein p53 Receptors, Progesterone Platinum Compounds Anticarcinogenic Agents Leucovorin RNA, Messenger

Analytical, Diagnostic and Therapeutic Techniques and Equipment80

SEER Program Drug Screening Assays, Antitumor Clinical Trials as Topic Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Survival Rate Incidence Early Detection of Cancer Survival Analysis Registries Retrospective Studies Neoplasm Staging Prognosis Follow-Up Studies Disease-Free Survival Combined Modality Therapy Risk Factors Drug Administration Schedule Research Design Clinical Trials, Phase III as Topic Multicenter Studies as Topic Risk Assessment Prospective Studies Radiotherapy Risk Cohort Studies Questionnaires Chemotherapy, Adjuvant Infusions, Intravenous Kaplan-Meier Estimate Patient Selection Carcinogenicity Tests Logistic Models Reproducibility of Results Mass Screening Odds Ratio Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Mammography Multivariate Analysis Maximum Tolerated Dose Sensitivity and Specificity Data Collection Radiotherapy, Adjuvant Drug Evaluation, Preclinical Gene Expression Profiling Administration, Oral Prevalence Radiotherapy Dosage Mastectomy, Segmental Epidemiologic Studies Confidence Intervals Neoplasms, Experimental Mastectomy, Simple Population Surveillance Lymph Node Excision Predictive Value of Tests Mastectomy Endpoint Determination Neoplasm Grading Drug Evaluation Xenograft Model Antitumor Assays Cross-Sectional Studies Program Evaluation Probability Radiation Monitoring Regression Analysis Pilot Projects Feasibility Studies Proportional Hazards Models Nutrition Surveys Mutagenicity Tests Models, Statistical Oligonucleotide Array Sequence Analysis Randomized Controlled Trials as Topic Remission Induction Drug Design Mortality Polymerase Chain Reaction Case-Control Studies

Psychiatry and Psychology3

Smoking Cooperative Behavior Interdisciplinary Communication

Phenomena and Processes14

Time Factors Risk Drug Resistance, Neoplasm Dose-Response Relationship, Drug Odds Ratio Genetic Predisposition to Disease Gene Expression Regulation, Neoplastic Maximum Tolerated Dose Sensitivity and Specificity Diet Mutation Probability Genotype Microsatellite Repeats

Disciplines and Occupations9

Medical Oncology Biomedical Research Research Design Research Translational Medical Research Radiation Oncology Drug Design Outcome Assessment (Health Care)Community-Based Participatory Research

Anthropology, Education, Sociology and Social Phenomena13

National Cancer Institute (U.S.)National Institutes of Health (U.S.)National Institute for Occupational Safety and Health (U.S.)Government Programs National Heart, Lung, and Blood Institute (U.S.)Quality of Life Age Distribution Forecasting Community Networks Health Education United States Food and Drug Administration International Cooperation Minority Groups

Technology, Industry, Agriculture1

Humanities2

Quality of Life History, 20th Century

Information Science19

SEER Program Survival Rate Incidence Registries Databases, Factual Questionnaires Information Services Databases as Topic Community Networks Data Collection Prevalence Internet Online Systems Hotlines Terminology as Topic Medical Informatics Mortality Interdisciplinary Communication Information Storage and Retrieval

Named Groups9

European Continental Ancestry Group Research Personnel African Americans Survivors Ethnic Groups Hispanic Americans African Continental Ancestry Group Infant, Newborn Continental Population Groups

Health Care85

National Cancer Institute (U.S.)National Institutes of Health (U.S.)Academies and Institutes SEER Program Cancer Care Facilities Research Support as Topic Clinical Trials as Topic Treatment Outcome Survival Rate Incidence Survival Analysis Registries Retrospective Studies Follow-Up Studies Disease-Free Survival Age Factors National Institute for Occupational Safety and Health (U.S.)American Cancer Society Risk Factors Institute of Medicine (U.S.)Pharmacy and Therapeutics Committee Tissue Banks Clinical Trials, Phase III as Topic Multicenter Studies as Topic Risk Assessment Prospective Studies Risk National Heart, Lung, and Blood Institute (U.S.)Cohort Studies Questionnaires National Health Programs Kaplan-Meier Estimate Patient Selection Logistic Models Reproducibility of Results Congresses as Topic Mass Screening Sex Factors Odds Ratio Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Financing, Government Professional Staff Committees Multivariate Analysis Age Distribution Community Networks Ethnic Groups Sensitivity and Specificity Data Collection Prevalence Confounding Factors (Epidemiology)Health Planning Guidelines Health Education Epidemiologic Studies Confidence Intervals Practice Guidelines as Topic International Agencies United States Food and Drug Administration Population Surveillance Predictive Value of Tests Health Services Accessibility Cost-Benefit Analysis Program Development Guidelines as Topic Healthcare Disparities Cross-Sectional Studies Program Evaluation Probability Radiation Monitoring Regression Analysis Community Health Services Pilot Projects Feasibility Studies Proportional Hazards Models Nutrition Surveys Models, Statistical Randomized Controlled Trials as Topic Occupational Exposure Mortality Physician's Practice Patterns Case-Control Studies Outcome Assessment (Health Care)Patient Participation Community-Based Participatory Research Radiation Injuries

Geographicals7

United States Canada Egypt Delaware Republic of Korea Great Britain Italy

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Humanities Information Science Named Groups Health Care Geographicals

National Cancer Institute (U.S.)National Institutes of Health (U.S.)United States Neoplasms Academies and Institutes SEER Program Antineoplastic Agents Cancer Care Facilities Drug Screening Assays, Antitumor Breast Neoplasms Research Support as Topic Clinical Trials as Topic Medical Oncology Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Survival Rate Incidence Early Detection of Cancer Survival Analysis Lung Neoplasms Registries Prostatic Neoplasms Biomedical Research Retrospective Studies Neoplasm Staging Prognosis Follow-Up Studies Ovarian Neoplasms Canada Disease-Free Survival Combined Modality Therapy Age Factors National Institute for Occupational Safety and Health (U.S.)American Cancer Society Risk Factors Institute of Medicine (U.S.)Databases, Factual Drug Administration Schedule Government Programs Colorectal Neoplasms Pharmacy and Therapeutics Committee Tissue Banks Colonic Neoplasms Research Design Clinical Trials, Phase III as Topic Multicenter Studies as Topic Risk Assessment Cisplatin Prospective Studies Neoplasm Metastasis Neoplasm Recurrence, Local Time Factors European Continental Ancestry Group Tumor Markers, Biological Stomach Neoplasms Research Radiotherapy Risk Paclitaxel National Heart, Lung, and Blood Institute (U.S.)Neoplasms, Second Primary Cohort Studies Questionnaires Adenocarcinoma Information Services Quality of Life Drug Resistance, Neoplasm Chemotherapy, Adjuvant Infusions, Intravenous National Health Programs Dose-Response Relationship, Drug Carcinoma, Non-Small-Cell Lung Databases as Topic Fluorouracil Cell Line, Tumor Organoplatinum Compounds Pancreatic Neoplasms Kaplan-Meier Estimate Patient Selection Disease Progression Neoplasm Invasiveness Carcinoma Carcinogenicity Tests Logistic Models Reproducibility of Results Deoxycytidine Research Personnel Uterine Cervical Neoplasms Urinary Bladder Neoplasms Congresses as Topic African Americans Smoking Mass Screening Sex Factors Odds Ratio Survivors Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Mammography Financing, Government

No FAQ available that match "national cancer institute"